Template:Ceftazidime: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Ceftazidime|{{fontcolor|#6C7B8B|Ceftazidime}}]]''''' | ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Ceftazidime|{{fontcolor|#6C7B8B|Ceftazidime}}]]''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | FORATZ<sup>®</sup> FDA Package Insert | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | FORATZ<sup>®</sup>,TAZICEF<sup>®</sup,CEFTAZIDIME<sup>®</sup FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime description|Description]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime description|Description]] | ||
Revision as of 19:39, 26 December 2013
| Ceftazidime |
|---|
| FORATZ®,TAZICEF®</sup,CEFTAZIDIME®</sup FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Overdosage |
| Clinical Studies |
| Dosage and Administration |
| How Supplied |
| Labels and Packages |